ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,165.36
0.60%
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs Yen
155.775
0.00%
Brent Oil
82.585
0.00%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) ニュース

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:TEVA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0920 : 53IH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/05/0820 : 00Business WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/05/0819 : 30Business WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/05/0307 : 30Business WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/05/0221 : 30Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/3017 : 00Business WireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/3017 : 00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/1706 : 43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/1706 : 30GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/1621 : 00Business WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/1121 : 30Business WireTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/1005 : 30Business WireTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/0702 : 00Business WireNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/0421 : 30Business WireTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/04/0121 : 30Business WireClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0806 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0806 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0806 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0806 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0806 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0806 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
2024/03/0606 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

最近閲覧した銘柄

NYSE
CVX
Chevron
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
FX
USDGBP
US Dollar vs Sterling
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
FX
USDJPY
US Dollar vs Yen
COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
FX
USDEUR
US Dollar vs Euro
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有